RedHill Biopharma Ltd. RedHill Biopharma Announces Positive and Unanimous DSMB Recommendation for Continuation of Phase III Study with RHB104 for Crohn's Disease

Following a preplanned review of safety data RedHill has received a unanimous recommendation from the independent Data and Safety Monitoring Board DSMB to continue the MAP US Phase III study...